CollPlant Ousts CEO Yehiel Tal, Names CFO Eran Rotem CEO and Halts Regenerative Medicine R&D
CLGN sits 55% above its 52-week low of $2.637 on light trading volume (0.1× avg).
Summary
CollPlant replaced CEO Yehiel Tal with CFO Eran Rotem effective immediately and is shutting down its regenerative medicine R&D to cut costs, while keeping rhCollagen production running.
Key Events · Executive and Board Changes · CLGN
-
CEO Replaced Effective Immediately
The board determined that Yehiel Tal will cease serving as CEO effective 2026-11-02; Eran Rotem, Deputy CEO and CFO, was appointed CEO the same day and retains the CFO role with compensation unchanged for now.
-
Regenerative Medicine R&D Discontinued
As part of a broader cost-reduction plan, the company is discontinuing its regenerative medicine research and development activities, cutting operating expenses but ending the tissue-regeneration pipeline.
-
Collagen Production Continues
rhCollagen manufacturing at the Yessod Hama'ala and Rehovot facilities is unaffected, and the company plans to keep supplying rhCollagen and rhCollagen-based bioinks to partners and customers.
-
Chairman Role Vacated
Tal also resigned as Interim Chairman effective the same date but remains a member of the Board; his separation payments follow his employment agreement, the compensation policy and applicable law, with no amount disclosed.
Analysis · CLGN · Industrial Applications And Services
The board removed CEO Yehiel Tal effective immediately and handed the role to Eran Rotem, who keeps the CFO title and unchanged pay — a consolidation of leadership that removes a layer rather than adding one. More consequential is the strategic retreat: the company is abandoning regenerative medicine research and development entirely, keeping only rhCollagen production and bioink supply to partners. For a company that carried a going-concern warning on its January shelf filing and has been leaning on small raises ($3.7M in October) and the LightSolver pivot, that is a survival move. It cuts cash burn but also writes off the medical-tissue pipeline that was the original equity story, leaving the investment case resting on collagen supply contracts and the newly acquired photonics business. Separation terms for Tal are not quantified in this filing.
How filings like this one have moved
In the 30 days to Nov 3, 2026, 40.9% of the 1143 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLGN was trading at $4.08 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.7M. The 52-week trading range was $2.64 to $22.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.